Recurrent pyogenic granuloma treated with topical imiquimod. 2006

Tara I Ezzell, and Jeffrey S Fromowitz, and Francisco A Ramos-Caro

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D005385 Fingers Four or five slender jointed digits in humans and primates, attached to each HAND. Finger
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077271 Imiquimod A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS. 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine,Aldara,R 837,R-837,S 26308,S-26308,Zyclara,R837
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000634 Aminoquinolines Quinolines substituted in any position by one or more amino groups.
D012871 Skin Diseases Diseases involving the DERMIS or EPIDERMIS. Dermatoses,Skin and Subcutaneous Tissue Disorders,Dermatosis,Skin Disease
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Tara I Ezzell, and Jeffrey S Fromowitz, and Francisco A Ramos-Caro
January 2009, Pediatric dermatology,
Tara I Ezzell, and Jeffrey S Fromowitz, and Francisco A Ramos-Caro
November 2007, The Australasian journal of dermatology,
Tara I Ezzell, and Jeffrey S Fromowitz, and Francisco A Ramos-Caro
December 2014, The British journal of dermatology,
Tara I Ezzell, and Jeffrey S Fromowitz, and Francisco A Ramos-Caro
January 2009, Pediatric dermatology,
Tara I Ezzell, and Jeffrey S Fromowitz, and Francisco A Ramos-Caro
January 2006, The Journal of dermatological treatment,
Tara I Ezzell, and Jeffrey S Fromowitz, and Francisco A Ramos-Caro
January 2006, Oral diseases,
Tara I Ezzell, and Jeffrey S Fromowitz, and Francisco A Ramos-Caro
February 1968, Plastic and reconstructive surgery,
Tara I Ezzell, and Jeffrey S Fromowitz, and Francisco A Ramos-Caro
April 1952, Oral surgery, oral medicine, and oral pathology,
Tara I Ezzell, and Jeffrey S Fromowitz, and Francisco A Ramos-Caro
December 2018, Annales de dermatologie et de venereologie,
Tara I Ezzell, and Jeffrey S Fromowitz, and Francisco A Ramos-Caro
January 2012, Actas dermo-sifiliograficas,
Copied contents to your clipboard!